{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T03:28:00Z","timestamp":1788492480248,"version":"build-2803163510"},"reference-count":112,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,6,22]],"date-time":"2022-06-22T00:00:00Z","timestamp":1655856000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001322","name":"South African Medical Research Council","doi-asserted-by":"publisher","award":["Research Capacity Development, Internship Programme"],"award-info":[{"award-number":["Research Capacity Development, Internship Programme"]}],"id":[{"id":"10.13039\/501100001322","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001321","name":"National Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001321","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"abstract":"<jats:p>\n                    Doxorubicin (Dox)-induced cardiotoxicity (DIC) remains a serious health burden, especially in developing countries. Unfortunately, the high cost of current preventative strategies has marginalized numerous cancer patients because of socio-economic factors. In addition, the efficacy of these strategies, without reducing the chemotherapeutic properties of Dox, is frequently questioned. These limitations have widened the gap and necessity for alternative medicines, like flavonoids, to be investigated. However, new therapeutics may also present their own shortcomings, ruling out the idea of \u201cnatural is safe\u201d. The U.S. Food and Drug Administration (FDA) has stipulated that the concept of drug-safety be considered in all pre-clinical and clinical studies, to explore the pharmacokinetics and potential interactions of the drugs being investigated. As such our studies on flavonoids, as cardio-protectants against DIC, have been centered around cardiac and cancer models, to ensure that the efficacy of Dox is preserved. Our findings thus far suggest that flavonoids of\n                    <jats:italic>Galenia africana<\/jats:italic>\n                    could be suitable candidates for the prevention of DIC. However, this still requires further investigation, which would focus on drug-interactions as well as\n                    <jats:italic>in vivo<\/jats:italic>\n                    experimental models to determine the extent of cardioprotection.\n                  <\/jats:p>","DOI":"10.3389\/fcvm.2022.907266","type":"journal-article","created":{"date-parts":[[2022,6,22]],"date-time":"2022-06-22T01:27:31Z","timestamp":1655861251000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":28,"title":["Prevention of Anthracycline-Induced Cardiotoxicity: The Good and Bad of Current and Alternative Therapies"],"prefix":"10.3389","volume":"9","author":[{"given":"Nonhlakanipho F.","family":"Sangweni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derick","family":"van Vuuren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lawrence","family":"Mabasa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kwazi","family":"Gabuza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Huisamen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharnay","family":"Naidoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reenen","family":"Barry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rabia","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,6,22]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1016\/j.jacbts.2016.05.008","article-title":"21st century cardio-oncology: identifying cardiac safety signals in the era of personalized medicine","volume":"1","author":"Sheng","year":"2016","journal-title":"JACC Basic Transl Sci."},{"key":"B2","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1016\/j.jacc.2014.06.1167","article-title":"Prevention of anthracycline-induced cardiotoxicity: challenges and opportunities","volume":"64","author":"Vejpongsa","year":"2014","journal-title":"J Am Coll Cardiol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.cels.2017.07.005","article-title":"Cell-cycle position of single MYC-driven cancer cells dictates their susceptibility to a chemotherapeutic drug","volume":"5","author":"Ryl","year":"2017","journal-title":"Cell Syst"},{"key":"B4","doi-asserted-by":"publisher","first-page":"3","DOI":"10.2174\/1570163812666150602144310","article-title":"Targeted cancer therapy: the next generation of cancer treatment","volume":"12","author":"Baudino","year":"2015","journal-title":"Curr Drug Discov Technol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.ejpb.2015.03.018","article-title":"Advanced targeted therapies in cancer: drug nanocarriers, the future of chemotherapy","volume":"93","author":"P\u00e9rez-Herrero","year":"2015","journal-title":"Eur J Pharm Biopharm."},{"key":"B6","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s11936-014-0315-4","article-title":"Anthracycline-induced cardiotoxicity: a review of pathophysiology, diagnosis, and treatment","volume":"16","author":"Raj","year":"2014","journal-title":"Curr Treat Options Cardiovasc Med."},{"key":"B7","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1007\/s10741-020-09977-1","article-title":"Anthracycline-induced cardiotoxicity and renin-angiotensin-aldosterone system\u2014from molecular mechanisms to therapeutic applications","volume":"27","author":"Sobczuk","year":"2022","journal-title":"Heart Fail Rev"},{"key":"B8","doi-asserted-by":"publisher","first-page":"26","DOI":"10.3389\/fcvm.2020.00026","article-title":"Cardiotoxicity of anthracyclines","volume":"7","author":"Cardinale","year":"2020","journal-title":"Front Cardiovasc Med."},{"key":"B9","unstructured":"2022"},{"key":"B10","unstructured":"Cancer Today2020"},{"key":"B11","volume-title":"Cancer Facts & Figures.","year":"2021"},{"key":"B12","unstructured":"CANSA - The Cancer Association of South AfricaPrevalence Cancer2021"},{"key":"B13","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1161\/CIRCRESAHA.119.314681","article-title":"Mitochondrial Determinants of Doxorubicin-Induced Cardiomyopathy","volume":"126","author":"Wallace Kendall","year":"2020","journal-title":"Circ Res."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.3389\/fonc.2021.650117","article-title":"Cancer in Africa: the untold story","volume":"11","author":"Hamdi","year":"2021","journal-title":"Front Oncol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.mrfmmm.2015.01.007","article-title":"Anthracyclines induce double-strand DNA breaks at active gene promoters","volume":"773","author":"Yang","year":"2015","journal-title":"Mutat Res."},{"key":"B16","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1111\/jphp.12539","article-title":"Increasing role of the cancer chemotherapeutic doxorubicin in cellular metabolism","volume":"68","author":"Meredith","year":"2016","journal-title":"J Pharm Pharmacol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.cbi.2019.01.003","article-title":"Synergistic anticancer activity of doxorubicin and piperlongumine on DU-145 prostate cancer cells \u2013 The involvement of carbonyl reductase 1 inhibition","volume":"300","author":"Piska","year":"2019","journal-title":"Chem Biol Interact."},{"key":"B18","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.fitote.2014.12.010","article-title":"Structure\u2013activity relationship of flavonoids as potent inhibitors of carbonyl reductase 1 (CBR1)","volume":"101","author":"Arai","year":"2015","journal-title":"Fitoterapia."},{"key":"B19","doi-asserted-by":"publisher","first-page":"108964","DOI":"10.1016\/j.biopha.2019.108964","article-title":"Pharmacokinetics and cardiotoxicity of doxorubicin and its secondary alcohol metabolite in rats","volume":"116","author":"Zeng","year":"2019","journal-title":"Biomed Pharmacother."},{"key":"B20","doi-asserted-by":"publisher","first-page":"101394","DOI":"10.1016\/j.redox.2019.101394","article-title":"Teaching the basics of the mechanism of doxorubicin-induced cardiotoxicity: have we been barking up the wrong tree?","volume":"29","author":"Kalyanaraman","year":"2019","journal-title":"Redox Biol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1007\/s12272-011-0411-x","article-title":"Effects of quercetin on the bioavailability of doxorubicin in rats: role of CYP3A4 and P-gp inhibition by quercetin","volume":"34","author":"Choi","year":"2011","journal-title":"Arch Pharm Res."},{"key":"B22","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1016\/j.jacc.2014.06.1175","article-title":"Translating stem cell research to cardiac disease therapies: pitfalls and prospects for improvement","volume":"64","author":"Rosen","year":"2014","journal-title":"J Am Coll Cardiol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s40959-019-0054-5","article-title":"Strategies to prevent anthracycline-induced cardiotoxicity in cancer survivors","volume":"5","author":"Bansal","year":"2019","journal-title":"Cardio-Oncol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1200\/JCO.18.01764","article-title":"Therapy-related cardiac risk in childhood cancer survivors: an analysis of the childhood cancer survivor study","volume":"373","author":"Bates","year":"2011","journal-title":"J Clin Oncol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"214","DOI":"10.2174\/157340311799960645","article-title":"Anthracycline cardiotoxicity: prevalence, pathogenesis and treatment","volume":"7","author":"Volkova","year":"2011","journal-title":"Cardiol Rev."},{"key":"B26","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1016\/j.jcmg.2017.11.017","article-title":"Assessment of left ventricular function by echocardiography: the case for routinely adding global longitudinal strain to ejection fraction","volume":"1","author":"Potter","year":"2018","journal-title":"JACC Cardiovasc Imaging 11, Part."},{"key":"B27","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1136\/heart.87.5.480","article-title":"Apoptosis in the cardiovascular system","volume":"87","author":"Bennett","year":"2021","journal-title":"Heart."},{"key":"B28","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1038\/s41419-021-03614-x","article-title":"Regulated cell death pathways in doxorubicin-induced cardiotoxicity","volume":"12","author":"Christidi","year":"2021","journal-title":"Cell Death Dis."},{"key":"B29","doi-asserted-by":"publisher","first-page":"2977","DOI":"10.1016\/j.bbamcr.2016.09.012","article-title":"Activation of apoptosis signalling pathways by reactive oxygen species","volume":"18632","author":"Redza-Dutordoir","year":"2016","journal-title":"Biochim Biophys Acta BBA Mol Cell Res."},{"key":"B30","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.taap.2016.01.006","article-title":"Inflammatory mediators in a short-time mouse model of doxorubicin-induced cardiotoxicity","volume":"293","author":"Pecoraro","year":"2016","journal-title":"Toxicol Appl Pharmacol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1080\/10715762.2017.1414208","article-title":"A combination of an iron chelator with an antioxidant exerts greater efficacy on cardioprotection than monotherapy in iron-overload thalassemic mice","volume":"52","author":"Kumfu","year":"2018","journal-title":"Free Radic Res."},{"key":"B32","doi-asserted-by":"publisher","first-page":"46663","DOI":"10.18632\/oncotarget.16944","article-title":"Autophagy and mitophagy in the context of doxorubicin-induced cardiotoxicity","volume":"88","author":"Koleini","year":"2017","journal-title":"Oncotarget."},{"key":"B33","doi-asserted-by":"publisher","first-page":"412","DOI":"10.2174\/1389200216888150915112039","article-title":"Role of drug metabolism in the cytotoxicity and clinical efficacy of anthracyclines","volume":"16","author":"Edwardson","year":"2015","journal-title":"Curr Drug Metab."},{"key":"B34","doi-asserted-by":"publisher","first-page":"1521020","DOI":"10.1155\/2017\/1521020","article-title":"Oxidative stress and cellular response to doxorubicin: a common factor in the complex milieu of anthracycline cardiotoxicity","volume":"2017","author":"Cappetta","year":"2017","journal-title":"Oxid Med Cell Longev."},{"key":"B35","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/j.freeradbiomed.2020.10.303","article-title":"Xanthine oxidase inhibition attenuates doxorubicin-induced cardiotoxicity in mice","volume":"162","author":"Tanaka","year":"2021","journal-title":"Free Radic Biol Med."},{"key":"B36","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.vph.2017.05.005","article-title":"Oxidative stress and reactive oxygen species in endothelial dysfunction associated with cardiovascular and metabolic diseases","volume":"100","author":"Incalza","year":"2018","journal-title":"Vascul Pharmacol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1186\/s13046-018-0772-9","article-title":"The PARP inhibitor olaparib potentiates the effect of the DNA damaging agent doxorubicin in osteosarcoma","volume":"37","author":"Park","year":"2018","journal-title":"J Exp Clin Cancer Res."},{"key":"B38","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1124\/mol.119.115725","article-title":"Insights into doxorubicin-induced cardiotoxicity: molecular mechanisms, preventive strategies, and early monitoring","volume":"96","author":"Wenningmann","year":"2019","journal-title":"Mol Pharmacol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1186\/s13046-021-01959-x","article-title":"Pyroptosis: a new paradigm of cell death for fighting against cancer","volume":"40","author":"Tan","year":"2021","journal-title":"J Exp Clin Cancer Res."},{"key":"B40","doi-asserted-by":"publisher","first-page":"2002","DOI":"10.1038\/s41598-018-37862-3","article-title":"Doxorubicin-induced cardiomyopathy associated with inhibition of autophagic degradation process and defects in mitochondrial respiration","volume":"9","author":"Abdullah","year":"2019","journal-title":"Sci Rep."},{"key":"B41","doi-asserted-by":"publisher","first-page":"679637","DOI":"10.3389\/fcell.2021.679637","article-title":"Autophagy-related LC3 accumulation interacted directly with LIR containing RIPK1 and RIPK3, stimulating necroptosis in hypoxic cardiomyocytes","volume":"9","author":"Huang","year":"2021","journal-title":"Front Cell Dev Biol."},{"key":"B42","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1007\/s00204-022-03262-w","article-title":"Molecular insights into the pathophysiology of doxorubicin-induced cardiotoxicity: a graphical representation","volume":"96","author":"Sangweni","year":"2022","journal-title":"Arch Toxicol"},{"key":"B43","doi-asserted-by":"publisher","first-page":"155","DOI":"10.3389\/fimmu.2018.00155","article-title":"The multirole of liposomes in therapy and prevention of infectious diseases","volume":"9","author":"Nisini","year":"2018","journal-title":"Front Immunol."},{"key":"B44","doi-asserted-by":"publisher","first-page":"120117","DOI":"10.1016\/j.ijpharm.2020.120117","article-title":"Liposomal doxorubicin as targeted delivery platform: current trends in surface functionalization","volume":"593","author":"Makwana","year":"2021","journal-title":"Int J Pharm."},{"key":"B45","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.2217\/pgs-2018-0124","article-title":"Reducing anthracycline-induced cardiotoxicity through pharmacogenetics","volume":"195","author":"Scott","year":"2018","journal-title":"Pharmacogenomics."},{"key":"B46","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.ijcha.2015.11.004","article-title":"Doxorubicin induced heart failure: phenotype and molecular mechanisms","volume":"10","author":"Mitry","year":"2015","journal-title":"Int J Cardiol Heart Vasc."},{"key":"B47","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1542\/peds.2012-0727","article-title":"Continuous versus bolus infusion of doxorubicin in children with all: long-term cardiac outcomes","volume":"130","author":"Lipshultz","year":"2012","journal-title":"Pediatrics."},{"key":"B48","doi-asserted-by":"publisher","first-page":"3754","DOI":"10.1161\/CIRCULATIONAHA.105.576850","article-title":"NAD(P)H oxidase and multidrug resistance protein genetic polymorphisms are associated with doxorubicin-induced cardiotoxicity","volume":"1124","author":"Wojnowski","year":"2005","journal-title":"Circulation."},{"key":"B49","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1016\/S1470-2045(10)70204-7","article-title":"Assessment of dexrazoxane as a cardioprotectant in doxorubicin-treated children with high-risk acute lymphoblastic leukaemia: long-term follow-up of a prospective, randomised, multicentre trial","volume":"110","author":"Lipshultz","year":"2010","journal-title":"Lancet Oncol."},{"key":"B50","doi-asserted-by":"publisher","first-page":"3555","DOI":"10.1002\/cncr.28256","article-title":"Impact of hemochromatosis gene mutations on cardiac status in doxorubicin-treated survivors of childhood high-risk leukemia","volume":"1199","author":"Lipshultz","year":"2013","journal-title":"Cancer."},{"key":"B51","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1093\/annonc\/mdj134","article-title":"Multicenter randomized phase III study of the cardioprotective effect of dexrazoxane (Cardioxane\u00ae) in advanced\/metastatic breast cancer patients treated with anthracycline-based chemotherapy","volume":"17","author":"Marty","year":"2006","journal-title":"Ann Oncol."},{"key":"B52","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1093\/jnci\/djq238","article-title":"Subsequent neoplasms in 5-year survivors of childhood cancer: the childhood cancer survivor study","volume":"1024","author":"Friedman","year":"2010","journal-title":"J Natl Cancer Inst."},{"key":"B53","doi-asserted-by":"publisher","first-page":"djv357","DOI":"10.1093\/jnci\/djv357","article-title":"Cardioprotection and second malignant neoplasms associated with dexrazoxane in children receiving anthracycline chemotherapy: a systematic review and meta-analysis","volume":"108","author":"Shaikh","year":"2016","journal-title":"J Natl Cancer Inst"},{"key":"B54","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1007\/s10557-020-06941-x","article-title":"The role of AMPK activation for cardioprotection in doxorubicin-induced cardiotoxicity","volume":"34","author":"Timm","year":"2020","journal-title":"Cardiovasc Drugs Ther."},{"key":"B55","unstructured":"Angiotensin converting enzyme inhibitors (ACEI)\n            HermanLL\n            PadalaSA\n            AhmedI\n            BashirK\n          Treasure Island, FLStatPearls PublishingStatPearls2022"},{"key":"B56","doi-asserted-by":"publisher","first-page":"2474","DOI":"10.1161\/CIRCULATIONAHA.106.635144","article-title":"Prevention of high-dose chemotherapy\u2013induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition","volume":"1143","author":"Cardinale","year":"2006","journal-title":"Circulation."},{"key":"B57","doi-asserted-by":"publisher","first-page":"2492","DOI":"10.1002\/cncr.21478","article-title":"Notable effects of angiotensin II receptor blocker, valsartan, on acute cardiotoxic changes after standard chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisolone","volume":"1041","author":"Nakamae","year":"2005","journal-title":"Cancer."},{"key":"B58","doi-asserted-by":"publisher","first-page":"2355","DOI":"10.1016\/j.jacc.2013.02.072","article-title":"Enalapril and carvedilol for preventing chemotherapy-induced left ventricular systolic dysfunction in patients with malignant hemopathies: The OVERCOME Trial (preventiOn of left Ventricular dysfunction with Enalapril and caRvedilol in patients submitted to intensive ChemOtherapy for the treatment of Malignant hEmopathies)","volume":"613","author":"Bosch","year":"2013","journal-title":"J Am Coll Cardiol."},{"key":"B59","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1016\/j.tcm.2019.01.001","article-title":"Effect of statins on atherosclerotic plaque","volume":"29","author":"Almeida","year":"2019","journal-title":"Trends Cardiovasc Med."},{"key":"B60","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1007\/s13105-013-0240-0","article-title":"Protective role of atorvastatin against doxorubicin-induced cardiotoxicity and testicular toxicity in mice","volume":"69","author":"Ramanjaneyulu","year":"2013","journal-title":"J Physiol Biochem."},{"key":"B61","doi-asserted-by":"publisher","first-page":"488","DOI":"10.3109\/15376516.2012.678406","article-title":"Cardioprotective effects of rosuvastatin and carvedilol on delayed cardiotoxicity of doxorubicin in rats","volume":"22","author":"Kim","year":"2012","journal-title":"Toxicol Mech Methods."},{"key":"B62","doi-asserted-by":"publisher","first-page":"2384","DOI":"10.1016\/j.jacc.2012.07.067","article-title":"Effect of statin therapy on the risk for incident heart failure in patients with breast cancer receiving anthracycline chemotherapy","volume":"603","author":"Seicean","year":"2012","journal-title":"J Am Coll Cardiol."},{"key":"B63","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1158\/0008-5472.CAN-08-3076","article-title":"Pretreatment with statin attenuates the cardiotoxicity of doxorubicin in mice","volume":"69","author":"Riad","year":"2009","journal-title":"Cancer Res."},{"key":"B64","unstructured":"Beta blockers\n            FarzamK\n            JanA\n          Treasure Island, FLStatPearls PublishingStatPearls2022"},{"key":"B65","doi-asserted-by":"publisher","first-page":"2258","DOI":"10.1016\/j.jacc.2006.07.052","article-title":"Protective effects of carvedilol against anthracycline-induced cardiomyopathy","volume":"481","author":"Kalay","year":"2006","journal-title":"J Am Coll Cardiol."},{"key":"B66","doi-asserted-by":"publisher","first-page":"5","DOI":"10.5603\/CJ.a2013.0150","article-title":"Effect of carvedilol on silent anthracycline-induced cardiotoxicity assessed by strain imaging: a prospective randomized controlled study with six-month follow-up","volume":"21","author":"Elitok","year":"2014","journal-title":"Cardiol J."},{"key":"B67","doi-asserted-by":"publisher","first-page":"2281","DOI":"10.1016\/j.jacc.2018.02.049","article-title":"Carvedilol for prevention of chemotherapy-related cardiotoxicity: the CECCY trial","volume":"710","author":"Avila","year":"2013","journal-title":"J Am Coll Cardiol."},{"key":"B68","doi-asserted-by":"publisher","first-page":"2306","DOI":"10.1016\/j.ijcard.2012.06.023","article-title":"Protective effects of nebivolol against anthracycline-induced cardiomyopathy: a randomized control study","volume":"167","author":"Kaya","year":"2013","journal-title":"Int J Cardiol."},{"key":"B69","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1161\/CIRCHEARTFAILURE.112.000055","article-title":"Cardioprotective effect of \u03b2-adrenoceptor blockade in patients with breast cancer undergoing chemotherapy","volume":"6","author":"Seicean","year":"2020","journal-title":"Circ Heart Fail"},{"key":"B70","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1002\/ehf2.13198","article-title":"Doxorubicin-induced and trastuzumab-induced cardiotoxicity in mice is not prevented by metoprolol","volume":"8","author":"Nicol","year":"2021","journal-title":"ESC Heart Fail."},{"key":"B71","doi-asserted-by":"publisher","first-page":"109784","DOI":"10.1016\/j.biopha.2019.109784","article-title":"Irigenin treatment alleviates doxorubicin (DOX)-induced cardiotoxicity by suppressing apoptosis, inflammation and oxidative stress via the increase of miR-425","volume":"125","author":"Guo","year":"2020","journal-title":"Biomed Pharmacother."},{"key":"B72","doi-asserted-by":"publisher","first-page":"3","DOI":"10.3390\/ani11030886","article-title":"Date palm pollen extract avert doxorubicin-induced cardiomyopathy fibrosis and associated oxidative\/nitrosative stress, inflammatory cascade, and apoptosis-targeting Bax\/Bcl-2 and Caspase-3 signaling pathways","volume":"11","author":"Elblehi","year":"2021","journal-title":"Animals"},{"key":"B73","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.jphs.2020.10.002","article-title":"Alleviation of the doxorubicin-induced nephrotoxicity by fasudil in vivo and in vitro","volume":"145","author":"Xiang","year":"2021","journal-title":"J Pharmacol Sci."},{"key":"B74","doi-asserted-by":"publisher","first-page":"117599","DOI":"10.1016\/j.lfs.2020.117599","article-title":"New molecular and biochemical insights of doxorubicin-induced hepatotoxicity","volume":"250","author":"Prasanna","year":"2020","journal-title":"Life Sci."},{"key":"B75","doi-asserted-by":"publisher","first-page":"923","DOI":"10.3389\/fimmu.2017.00923","article-title":"Natural biflavonoids modulate macrophage\u2013oxidized LDL interaction in vitro and promote atheroprotection in vivo","volume":"8","author":"Tabares-Guevara","year":"2017","journal-title":"Front Immunol"},{"key":"B76","doi-asserted-by":"publisher","first-page":"9","DOI":"10.3389\/fchem.2018.00009","article-title":"Systematic chemical analysis approach reveals superior antioxidant capacity via the synergistic effect of flavonoid compounds in red vegetative tissues","volume":"6","author":"Qin","year":"2018","journal-title":"Front Chem."},{"key":"B77","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.3389\/fphar.2020.574496","article-title":"Combination of balsamin and flavonoids induce apoptotic effects in liver and breast cancer cells","volume":"11","author":"Ajji","year":"2020","journal-title":"Front Pharmacol."},{"key":"B78","doi-asserted-by":"publisher","first-page":"113888","DOI":"10.1016\/j.bcp.2020.113888","article-title":"Dihydromyricetin alleviates doxorubicin-induced cardiotoxicity by inhibiting NLRP3 inflammasome through activation of SIRT1","volume":"175","author":"Sun","year":"2020","journal-title":"Biochem Pharmacol."},{"key":"B79","doi-asserted-by":"publisher","first-page":"113","DOI":"10.3389\/fphys.2020.00113","article-title":"Luteolin attenuates doxorubicin-induced cardiotoxicity through promoting mitochondrial autophagy","volume":"11","author":"Xu","year":"2020","journal-title":"Front Physiol."},{"key":"B80","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1097\/FJC.0000000000000827","article-title":"Cardioprotective effects of latifolin against doxorubicin-induced cardiotoxicity by macrophage polarization in mice","volume":"75","author":"Zhang","year":"2020","journal-title":"J Cardiovasc Pharmacol."},{"key":"B81","doi-asserted-by":"publisher","first-page":"116623","DOI":"10.1016\/j.lfs.2019.116623","article-title":"Apigenin attenuates doxorubicin induced cardiotoxicity via reducing oxidative stress and apoptosis in male rats","volume":"232","author":"Zare","year":"2019","journal-title":"Life Sci."},{"key":"B82","doi-asserted-by":"publisher","first-page":"84","DOI":"10.4103\/0973-7847.194044","article-title":"Overviews of biological importance of quercetin: a bioactive flavonoid","volume":"100","author":"Anand David","year":"2016","journal-title":"Pharmacogn Rev."},{"key":"B83","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1186\/1423-0127-20-95","article-title":"Quercetin-induced cardioprotection against doxorubicin cytotoxicity","volume":"20","author":"Chen","year":"2013","journal-title":"J Biomed Sci."},{"key":"B84","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1080\/15376516.2018.1564948","article-title":"Quercetin protects cardiomyocytes against doxorubicin-induced toxicity by suppressing oxidative stress and improving mitochondrial function via 14-3-3\u03b3","volume":"29","author":"Chen","year":"2019","journal-title":"Toxicol Mech Methods."},{"key":"B85","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1111\/bph.15350","article-title":"Quercetin induces p53-independent cancer cell death through lysosome activation by the transcription factor EB and Reactive Oxygen Species-dependent ferroptosis","volume":"178","author":"Wang","year":"2021","journal-title":"Br J Pharmacol."},{"key":"B86","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-017-09673-5","article-title":"Quercetin prevents hepatic fibrosis by inhibiting hepatic stellate cell activation and reducing autophagy via the TGF-\u03b21\/Smads and PI3K\/Akt pathways","volume":"7","author":"Wu","year":"2017","journal-title":"Sci Rep"},{"key":"B87","doi-asserted-by":"publisher","first-page":"4440","DOI":"10.1111\/bph.12795","article-title":"Quercetin attenuates doxorubicin cardiotoxicity by modulating Bmi-1 expression","volume":"1719","author":"Dong","year":"2014","journal-title":"Br J Pharmacol."},{"key":"B88","doi-asserted-by":"publisher","first-page":"476","DOI":"10.3389\/fonc.2020.00476","article-title":"Altered iron metabolism and impact in cancer biology, metastasis, and immunology","volume":"10","author":"Brown","year":"2020","journal-title":"Front Oncol."},{"key":"B89","doi-asserted-by":"publisher","first-page":"819","DOI":"10.3892\/or.2017.5766","article-title":"Anticancer and apoptosis-inducing effects of quercetin in vitro and in vivo","volume":"38","author":"Hashemzaei","year":"2017","journal-title":"Oncol Rep"},{"key":"B90","doi-asserted-by":"publisher","first-page":"1602","DOI":"10.3892\/or.2015.4481","article-title":"Quercetin inhibits angiogenesis through thrombospondin-1 upregulation to antagonize human prostate cancer PC-3 cell growth in vitro and in vivo","volume":"35","author":"Yang","year":"2016","journal-title":"Oncol Rep"},{"key":"B91","doi-asserted-by":"publisher","first-page":"2306","DOI":"10.3390\/nu12082306","article-title":"Inhibitory effects of quercetin and its main methyl, sulfate, and glucuronic acid conjugates on cytochrome P450 enzymes, on OATP, BCRP and MRP2 Transporters Nutrients","volume":"12","author":"Mohos","year":"2020"},{"key":"B92","article-title":"Studying the inhibitory effect of quercetin and thymoquinone on human cytochrome P450 enzyme activities","volume-title":"Pharmacogn Mag","author":"Elbarbry","year":"2017"},{"key":"B93","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.3389\/fphar.2020.01172","article-title":"The prophylactic effect of pinocembrin against doxorubicin-induced cardiotoxicity in an in vitro H9c2 cell model","volume":"11","author":"Sangweni","year":"2020","journal-title":"Front Pharmacol."},{"key":"B94","doi-asserted-by":"publisher","first-page":"2323","DOI":"10.3390\/molecules24122323","article-title":"Advances in biosynthesis, pharmacology, and pharmacokinetics of pinocembrin, a promising natural small-molecule drug","volume":"242","author":"Shen","year":"2019","journal-title":"Molecules."},{"key":"B95","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1016\/j.jsps.2020.08.004","article-title":"Galenia africana plant extract exhibits cytotoxicity in breast cancer cells by inducing multiple programmed cell death pathways","volume":"280","author":"Mohamed","year":"2020","journal-title":"Saudi Pharm J SPJ."},{"key":"B96","doi-asserted-by":"publisher","first-page":"107533","DOI":"10.1016\/j.intimp.2021.107533","article-title":"Pinocembrin inhibited cardiomyocyte pyroptosis against doxorubicin-induced cardiac dysfunction via regulating Nrf2\/Sirt3 signaling pathway","volume":"95","author":"Gu","year":"2021","journal-title":"Int Immunopharmacol."},{"key":"B97","doi-asserted-by":"publisher","first-page":"10","DOI":"10.3390\/molecules22101589","article-title":"Aspalathin reverts doxorubicin-induced cardiotoxicity through increased autophagy and decreased expression of p53\/mTOR\/p62 signaling","volume":"220","author":"Johnson","year":"2017","journal-title":"Molecules"},{"key":"B98","doi-asserted-by":"publisher","first-page":"4","DOI":"10.18433\/J3BK5T","article-title":"Pre-clinical pharmacokinetic and pharmacodynamic characterization of selected chiral flavonoids: pinocembrin and pinostrobin","volume":"18","author":"Sayre","year":"2015","journal-title":"J Pharm Pharm Sci"},{"key":"B99","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/srep29340","article-title":"In-vivo absorption of pinocembrin-7-O-\u03b2-D-glucoside in rats and its in-vitro biotransformation","volume":"6","author":"Guo","year":"2016","journal-title":"Sci Rep"},{"key":"B100","doi-asserted-by":"publisher","first-page":"10","DOI":"10.3390\/molecules26103018","article-title":"Characterization of the CYP3A4 enzyme inhibition potential of selected flavonoids","volume":"260","author":"Kond\u017da","year":"2021","journal-title":"Molecules."},{"key":"B101","doi-asserted-by":"publisher","first-page":"2165","DOI":"10.1016\/0006-2952(92)90343-H","article-title":"The consequences of doxorubicin quinone reduction in vivo in tumour tissue","volume":"441","author":"Cummings","year":"1992","journal-title":"Biochem Pharmacol."},{"key":"B102","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.toxlet.2008.06.858","article-title":"Inactivation of the anticancer drugs doxorubicin and oracin by aldo\u2013keto reductase (AKR) 1C3","volume":"181","author":"Novotna","year":"2008","journal-title":"Toxicol Lett."},{"key":"B103","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/j.jsps.2014.04.008","article-title":"Drug safety: The concept, inception and its importance in patients' health","volume":"24","author":"Alshammari","year":"2016","journal-title":"Saudi Pharm J SPJ."},{"key":"B104","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1111\/j.1365-2125.1995.tb05796.x","article-title":"The role of human cytochrome P450 enzymes in the metabolism of anticancer agents: implications for drug interactions","volume":"40","author":"Kivisto","year":"1995","journal-title":"Br J Clin Pharmacol."},{"key":"B105","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/sj.tpj.6500285","article-title":"Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity","volume":"5","author":"Ingelman-Sundberg","year":"2005","journal-title":"Pharmacogenomics J."},{"key":"B106","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/sj.onc.1209377","article-title":"Cytochrome P450 pharmacogenetics and cancer","volume":"251","author":"Rodriguez-Antona","year":"2006","journal-title":"Oncogene."},{"key":"B107","unstructured":"DouediS\n            CarsonMP\n          StatPearls PublishingAnthracycline Medications (Doxorubicin)2021"},{"key":"B108","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1007\/s10557-016-6711-0","article-title":"Anthracycline chemotherapy and cardiotoxicity","volume":"31","author":"McGowan","year":"2017","journal-title":"Cardiovasc Drugs Ther."},{"key":"B109","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/j.ejmhg.2017.03.001","article-title":"CYP2D6 pharmacogenomics","volume":"18","author":"Gopisankar","year":"2017","journal-title":"Egypt J Med Hum Genet."},{"key":"B110","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/jpm8010008","article-title":"Pharmacogenomic impact of CYP2C19 variation on clopidogrel therapy in precision cardiovascular medicine","volume":"8","author":"Brown","year":"2018","journal-title":"J Pers Med."},{"key":"B111","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1503\/cmaj.082001","article-title":"A population-based study of the drug interaction between proton pump inhibitors and clopidogrel","volume":"180","author":"Juurlink","year":"2009","journal-title":"Can Med Assoc J."},{"key":"B112","doi-asserted-by":"publisher","first-page":"504","DOI":"10.5009\/gnl16352","article-title":"Pantoprazole does not reduce the antiplatelet effect of clopidogrel: a randomized controlled trial in Korea","volume":"11","author":"Choi","year":"2017","journal-title":"Gut Liver."}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2022.907266\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,22]],"date-time":"2022-06-22T01:27:35Z","timestamp":1655861255000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2022.907266\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,22]]},"references-count":112,"alternative-id":["10.3389\/fcvm.2022.907266"],"URL":"https:\/\/doi.org\/10.3389\/fcvm.2022.907266","relation":{},"ISSN":["2297-055X"],"issn-type":[{"value":"2297-055X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,22]]},"article-number":"907266"}}